Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health. They do so by leveraging clinical data in order to achieve the best results possible.
EHave，Inc.。(场外交易代码：EHVVF)是一家领先的医疗服务和技术公司，专注于通过设计新的化合物和新的治疗方案来治疗大脑健康，将迷幻药进展为治疗药物。他们通过利用临床数据来实现这一点，以获得尽可能好的结果。
Entheon Biomedical Corp. (OTCQB:ENTBF) is a wholly-owned subsidiary of HaluGen Life Sciences Inc., a company that has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, improving patient care while reducing side effects and risk. Therefore, HaluGen's genetic-based platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs with test results within days.
Entheon Biomedical公司。(OTCQB：ENTBF)是一家全资子公司HaluGen生命科学公司.，一家开发了DNA测试和个性化迷幻预筛查平台的公司，该平台提供遗传、个人和家庭洞察，以更好地告知迷幻体验，改善患者护理，同时减少副作用和风险。因此，HaluGen的基于基因的平台有助于在几天内使用具有测试结果的致幻药物时评估个人的整体敏感性和风险概况。
Both companies have combined their efforts and the result is a new expanded psychedelics genetic testing panel for Ehave's subsidiary psychedelics company, KetaDASH. The device will analyze a series of relevant DNA biomarkers and use pre-screening mental health surveys to understand a given individual's risk and potential of adverse reactions with the use of ketamine.
两家公司已经联合起来努力结果是eHave的子公司迷幻药公司的一个新的扩展迷幻药基因测试小组，凯塔·达什。该设备将分析一系列相关的DNA生物标记物，并使用预先筛查的精神健康调查，以了解特定个人使用氯胺酮的不良反应的风险和可能性。
The new device will provide results that will be, then, absolutely personal.
新设备将提供结果那么，这将是绝对的个人隐私。
On the other hand, genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. Specifically, the gene mutation CYP2B6 can influence the metabolism of ketamine for the 10-20% of people that carry a specific variant. Similarly, the HTR2A gene mutation, present in nearly 20% of the population, can impact how a person responds to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT.
另一方面，遗传学可以在决定个体对迷幻辅助心理治疗的反应方面发挥关键作用。具体地说，基因突变CYP2B6会影响10%-20%携带特定变异的人的氯胺酮代谢。同样，HTR2A基因突变存在于近20%的人口中，可以影响人对5-羟色胺的反应，5-羟色胺是裸盖菇素、LSD和DMT等5-羟色胺能迷幻剂的主要作用机制。
It is expected that precision medicine will provide KetaDASH with the ability to tailor the treatment based on an individual or sub-groups variability in genes and lifestyle choice.
预计精确医学将为KetaDASH提供根据个人或亚组基因和生活方式选择的变异性进行量身定制治疗的能力。
As Ehave CEO Ben Kaplan put it, "The benefit of the psychedelic profile is that it will enable the individuals and healthcare professionals at KetaDASH to personalize psychedelic therapy by providing an individual's metabolic status for ketamine with their CYP2B6 genotype."
作为eHave首席执行官本·卡普兰换言之，“迷幻档案的好处是，它将使KetaDASH的个人和医疗保健专业人员能够通过提供带有他们的CYP2B6基因的氯胺酮的代谢状态来个性化迷幻疗法。”
This is a point of view shared by Entheon CEO Timothy Ko. "We believe that personalization will become an increasingly important feature of the psychedelic therapeutics landscape."
这一观点得到了Entheon首席执行官蒂莫西·科。我们相信，个性化将成为迷幻疗法的一个日益重要的特征。“
Photo Courtesy of Pixabay
图片由Pixabay提供
译文内容由第三方软件翻译。